A Novel Polymer-Encapsulated Multi-Imaging Modality Fiducial Marker with Positive Signal Contrast for Image-Guided Radiation Therapy.

Autor: Wang L; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Sanders J; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Ward JF; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Lee SR; Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Poenisch F; Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Swanson DM; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Sahoo N; Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Zhu XR; Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Ma J; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Kudchadker RJ; Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Choi SL; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Nguyen QN; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Mayo LL; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Shah SJ; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Frank SJ; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2024 Jan 31; Vol. 16 (3). Date of Electronic Publication: 2024 Jan 31.
DOI: 10.3390/cancers16030625
Abstrakt: Background: Current fiducial markers (FMs) in external-beam radiotherapy (EBRT) for prostate cancer (PCa) cannot be positively visualized on magnetic resonance imaging (MRI) and create dose perturbation and significant imaging artifacts on computed tomography (CT) and MRI. We report our initial experience with clinical imaging of a novel multimodality FM, NOVA.
Methods: We tested Gold Anchor [G-FM], BiomarC [carbon, C-FM], and NOVA FMs in phantoms imaged with kilovoltage (kV) X-rays, transrectal ultrasound (TRUS), CT, and MRI. Artifacts of the FMs on CT were quantified by the relative streak artifacts level (rSAL) metric. Proton dose perturbations (PDPs) were measured with Gafchromic EBT3 film, with FMs oriented either perpendicular to or parallel with the beam axis. We also tested the performance of NOVA-FMs in a patient.
Results: NOVA-FMs were positively visualized on all 4 imaging modalities tested. The rSAL on CT was 0.750 ± 0.335 for 2-mm reconstructed slices. In F-tests, PDP was associated with marker type and depth of measurement ( p < 10 -6 ); at 5-mm depth, PDP was significantly greater for the G-FM (12.9%, p = 10 -6 ) and C-FM (6.0%, p = 0.011) than NOVA (4.5%). EBRT planning with MRI/CT image co-registration and daily alignments using NOVA-FMs in a patient was feasible and reproducible.
Conclusions: NOVA-FMs were positively visible and produced less PDP than G-FMs or C-FMs. NOVA-FMs facilitated MRI/CT fusion and identification of regions of interest.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje